Literature DB >> 8985636

Ocular penetration and pharmacokinetics of topical fluconazole.

R W Yee1, C J Cheng, S Meenakshi, T M Ludden, J E Wallace, M G Rinaldi.   

Abstract

The high bioavailability and low toxicity of fluconazole, a stable, water-soluble, low-molecular-weight bis-triazole antifungal, makes it a good candidate for consideration as a topical ocular agent. The penetration of fluconazole (0.2%) into the corneas and aqueous humors of New Zealand white rabbits was assayed by gas liquid chromatography (GLC). Peak corneal levels occurred essentially immediately at 5 min in the corneas [debrided, 8.2 +/- 1.2 micrograms/g; nondebrided, 1.6 +/- 0.6 microgram/g; (mean +/- SEM)] and at 15 min after application in the aqueous [debrided, 9.4 +/- 2.3 micrograms/ml; nondebrided, 1.6 +/- 0.6 microgram/ml; (mean +/- SEM)]. Estimating from semilogarithmic plots of the data, the halflife (t1/2) in the debrided eyes was 15 min; in the nondebrided eyes, t1/2 was 30 min. A loading dose of a 20-microliter drop per min for 5 min yielded levels of 59.9 +/- 11.3 micrograms/g (mean +/- SEM) in the debrided corneas and 32.4 +/- 1.9 micrograms/ ml (mean +/- SEM) in the corresponding aqueous humor. A regimen consisting of this loading dose followed by one 20 microliters drop/h for 6 h showed 45.9 +/- 3.5 micrograms/g (mean +/- SEM) in the debrided corneas and 8.8 +/- 1.7 micrograms/ml (mean +/- SEM) in the corresponding aqueous. The same regimen yielded values of 3.1 +/- 0.2 micrograms/g in the nondebrided corneas and 1.3 +/- 0.2 micrograms/ml (mean +/- SEM) in the aqueous. Minimal inhibitory concentrations (MIC) at 24 h for yeasts ranged from < 1.25 to 20 micrograms/ml, for hyaline molds from 2.5 to > 20 micrograms/ml, and dematiaceous molds from < 1.25 to > 20 micrograms/ml. Topical fluconazole exhibits pharmacokinetics and selective MICs that merit further evaluation for its ophthalmic use as a topical antifungal agent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985636

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model.

Authors:  David Goldblum; Beatrice E Frueh; Gian-Marco Sarra; Konstantinos Katsoulis; Stefan Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 2.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

3.  Genotypic identification of Fusarium species from ocular sources: comparison to morphologic classification and antifungal sensitivity testing (an AOS thesis).

Authors:  Eduardo C Alfonso
Journal:  Trans Am Ophthalmol Soc       Date:  2008

4.  Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes.

Authors:  Ola H El-Nesr; Soad A Yahiya; Omaima N El-Gazayerly
Journal:  Saudi Pharm J       Date:  2010-07-25       Impact factor: 4.330

5.  Ocular infections caused by Scedosporium apiospermum: A case series.

Authors:  Seema Ramakrishnan; Kunal Mandlik; Tejashree Sanket Sathe; Joseph Gubert; Thiruvengada Krishnan; Prabu Baskaran
Journal:  Indian J Ophthalmol       Date:  2018-01       Impact factor: 1.848

6.  Keratomycosis in captive red pandas (Ailurus fulgens): 2 cases.

Authors:  Hayley August Volk; Anu O'Reilly; Kate Bodley; Helen McCracken
Journal:  Open Vet J       Date:  2018-06-01

7.  Candida parapsilosis keratitis treated successfully with topical and oral fluconazole.

Authors:  Pei-Hsuan Li; Chun-Chen Chen; Shiow-Wen Liou
Journal:  Taiwan J Ophthalmol       Date:  2016-06-01

8.  A stepwise optimization strategy to formulate in situ gelling formulations comprising fluconazole-hydroxypropyl-beta-cyclodextrin complex loaded niosomal vesicles and Eudragit nanoparticles for enhanced antifungal activity and prolonged ocular delivery.

Authors:  Heba Elmotasem; Ghada E A Awad
Journal:  Asian J Pharm Sci       Date:  2019-12-24       Impact factor: 6.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.